Metabolic Health

The metabolic health crisis is multidimensional—encompassing type 2 diabetes, obesity, MASH/MASLD, cardiovascular disease, kidney disease, and related conditions—all driven by shared underlying dysfunction (insulin resistance, inflammation, mitochondrial impairment).
AMCP Metabolic Health Thought Leadership Program
AMCP Metabolic Health Thought Leadership Program
Resource

Metabolic Health Initiative: Reimagining Managed Care Strategies

AMCP launched the metabolic health thought leadership program to empower payers to shift from siloed treatment to holistic, root-cause-focused metabolic health management—redefining roles in benefit design and population outcomes—starting immediately with the new ADA 2026 CGM expansions that are reshaping coverage and access.
Metabolic Health
Capitol Behind Trees
Letters, Statements & Analysis

Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s

President Donald Trump announced a series of agreements with Eli Lilly and Company and Novo Nordisk to offer Most-Favored-Nation (MFN) prices on two GLP-1 therapies, semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand names Mounjaro and Zepbound). This marks the fourth and fifth publicly announced agreements between the Trump administration and pharmaceutical manufacturers, joining earlier announcements with Pfizer, AstraZeneca, and EMD Serono. The manufacturers also agreed to cap prices for insulin products and other commonly prescribed diabetes medications.
Metabolic Health, Legislation & Regulation